-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
BDX delivered solid Q2 FY 26 (Sep.) results with revenue growth of 5.2% to $4.714B and adjusted EPS of $2.90 (+3.9%) beating the consensus by $0.10. The quarter featured BDX's major "Excellence Unleashed" restructuring initiative with $487M in charges including $450M of non-cash asset impairments as the company simplifies operations. This strategic repositioning positions BDX for improved operational efficiency and margin expansion, in our view. The company raised full-year adjusted EPS guidance to $12.52-$12.72 from the prior $12.35-$12.65 range while reaffirming low single-digit revenue growth expectations. Segment performance showed balanced growth with Interventional leading at +7.3% to $1.357B and Connected Care delivering +4.9% to $1.120B. We believe balanced capital allocation, including $2.0B accelerated share repurchases and $2.1B debt retirement, demonstrates management's commitment to shareholder returns while investing in operational improvements.